Detailed Narrative
Q3 FY26 Performance Overview
Sanjivani Paranteral Limited reported a strong Q3 FY26, with consolidated revenue growing 27.1% year-on-year to INR 22.1 crores. Consolidated EBITDA saw a significant increase of 44.8% to INR 14.1 crores, leading to an expanded EBITDA margin of 18.5% compared to 16.2% in Q3 FY25. Profit after tax (PAT) also surged by 46.3% year-on-year to INR 2.38 crores, reflecting improved operational efficiency and product mix.
Segmental Performance and Growth Drivers
The base business (stand-alone) revenue stood at INR 20.9 crores, marking a 20.2% year-on-year growth, primarily driven by higher shipments due to easing logistics and a favorable product mix. While injectable revenues declined 9.7% to INR 11.7 crores, oral revenues demonstrated robust growth of 153.3% to INR 8.6 crores. Exports remained a dominant contributor, accounting for 76.9% of the total revenue, with core markets in the Middle East, Africa, and Latin America being key.
New Growth Platforms: SPL Infusion and Nutraceuticals
The quarter marked a significant milestone with the first-time revenue contribution of INR 1.2 crores from SPL Infusion Private Limited, the company's new IV fluids facility in Pune. This facility is currently operating at 23-25% capacity, with a target to reach 40-50% utilization in FY27 and a peak revenue potential of over INR 120-130 crores at 19-20% EBITDA margin. The Prague-based nutraceutical venture also continued to gain commercial traction, contributing INR 0.56 crores in revenue.
Outlook and Guidance for FY26 & FY27
Management projects the full FY26 base business revenue to close between INR 73-75 crores. For FY27, the company targets a top line of INR 90 crores from its base business and an additional INR 60-65 crores from SPL Infusion. EBITDA margins for the base business are expected to remain in the 16-17% range, while the Pune business aims for 17-18% EBITDA, with further upside as utilization improves. The base business is anticipated to grow at 18-20% from Q2/Q3 FY27.
Capital Allocation and Promoter Shareholding
The company's major capex cycle is largely complete. For FY27, a recurring capex of INR 4-4.5 crores is planned for upgrading and maintaining existing facilities in Mumbai and Dehradun. Promoters have demonstrated strong commitment by converting 6 lakh warrants this year, infusing capital into the company. They expressed a continuous intent to increase their shareholding year-on-year, adhering to regulatory limits.
Regulatory Compliance and Market Positioning
Sanjivani Paranteral Limited announced that all its plants are compliant with the recently revised Schedule M by the FDA, a standard that only 20-30% of plants in India are estimated to meet. This compliance positions the company favorably in a market with increasing regulatory scrutiny. The company also highlighted its unique combination of infusions, small volume injections, tablets, capsules, and nutraceuticals under one umbrella, which enhances its market presence and distributor appeal.